DSG Capital Advisors LLC Makes New $1.46 Million Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

DSG Capital Advisors LLC acquired a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 3,625 shares of the pharmaceutical company's stock, valued at approximately $1,460,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Capital World Investors boosted its holdings in Vertex Pharmaceuticals by 5.7% in the 4th quarter. Capital World Investors now owns 28,325,695 shares of the pharmaceutical company's stock worth $11,406,667,000 after buying an additional 1,514,993 shares during the period. Vanguard Group Inc. boosted its holdings in Vertex Pharmaceuticals by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 23,258,288 shares of the pharmaceutical company's stock worth $9,366,113,000 after buying an additional 98,654 shares during the period. Capital Research Global Investors boosted its holdings in Vertex Pharmaceuticals by 15.8% in the 4th quarter. Capital Research Global Investors now owns 10,428,951 shares of the pharmaceutical company's stock worth $4,199,713,000 after buying an additional 1,426,746 shares during the period. Wellington Management Group LLP boosted its holdings in Vertex Pharmaceuticals by 23.3% in the 4th quarter. Wellington Management Group LLP now owns 5,916,084 shares of the pharmaceutical company's stock worth $2,382,407,000 after buying an additional 1,117,214 shares during the period. Finally, Loomis Sayles & Co. L P boosted its holdings in Vertex Pharmaceuticals by 23.0% in the 4th quarter. Loomis Sayles & Co. L P now owns 3,772,789 shares of the pharmaceutical company's stock worth $1,519,302,000 after buying an additional 704,575 shares during the period. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Trading Up 0.4%

Shares of VRTX traded up $1.99 during trading hours on Thursday, reaching $447.09. 882,371 shares of the company traded hands, compared to its average volume of 1,418,078. The company's fifty day moving average price is $470.99 and its two-hundred day moving average price is $461.47. The company has a market capitalization of $114.81 billion, a price-to-earnings ratio of -203.22, a price-to-earnings-growth ratio of 2.11 and a beta of 0.51. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. The business had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.85 billion. During the same period in the previous year, the firm earned $4.76 EPS. The company's revenue was up 2.6% on a year-over-year basis. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on the stock. BMO Capital Markets set a $545.00 price target on shares of Vertex Pharmaceuticals in a report on Friday, January 31st. Wells Fargo & Company downgraded shares of Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $460.00 price target for the company. in a report on Thursday, January 30th. Canaccord Genuity Group raised shares of Vertex Pharmaceuticals from a "sell" rating to a "hold" rating and raised their price target for the company from $408.00 to $424.00 in a report on Tuesday, February 11th. Royal Bank of Canada raised their price target on shares of Vertex Pharmaceuticals from $420.00 to $423.00 and gave the company a "sector perform" rating in a report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. raised their price target on shares of Vertex Pharmaceuticals from $512.00 to $515.00 and gave the company an "overweight" rating in a report on Tuesday, May 6th. Fourteen research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $515.04.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP David Altshuler sold 3,231 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the completion of the transaction, the executive vice president now directly owns 26,512 shares of the company's stock, valued at approximately $13,256,000. The trade was a 10.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.